Microsomal P450-mediated monooxygenase activity supported by NADPH requires an interaction between flavoprotein NADPH-cytochrome P450 reductase and cytochrome P450. These proteins have been identified as the simplest system (with the inclusion of a phospholipid (PL) component) that possesses monooxygenase function; however, little is known about the organization of these proteins in the microsomal membrane. Although reductase and P450 are known to form a 1:1 functional complex, there exists a 10- to 20-fold excess of P450 over the reductase. This raises several questions including "How are the enzymes of the P450 system organized in the microsomal membrane?" and "Can one P450 enzyme affect the functional characteristics of another P450?" This review summarizes evidence supporting the potential for enzymes involved in the P450 system to interact, focusing on the interactions between reductase and P450 and interactions between multiple P450 enzymes. Studies on the aggregation characteristics of P450 as well as on rotational diffusion are detailed, with a special emphasis on the potential for P450 enzymes to produce oligomeric complexes and to suggest the environment in which P450 exists in the endoplasmic reticulum. Finally, more recent studies describing the potential for multiple P450s to exist as complexes and their effect on P450 function are presented, including studies using reconstituted systems as well as systems where two P450s are coexpressed in the presence of reductase. An understanding of the interactions among reductase and multiple P450s is important for predicting conditions where the drug disposition may be altered by the direct effects of P450-P450 complex formation. Furthermore, the potential for one P450 enzyme to affect the behavior of another P450 may be extremely important for drug screening and development, requiring metabolic screening of a drug with reconstituted systems containing multiple P450s rather than simpler systems containing only a single form.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0163-7258(03)00031-7 | DOI Listing |
Toxicol Sci
January 2025
Takeda Development Center Americas, Inc, Cambridge, MA, USA.
The frequency of drug-induced liver injury (DILI) in clinical trials remains a challenge for drug developers despite advances in human hepatotoxicity models and improvements in reducing liver-related attrition in preclinical species. TAK-994, an oral orexin receptor 2 agonist, was withdrawn from phase II clinical trials due to the appearance of severe DILI. Here, we investigate the likely mechanism of TAK-994 DILI in hepatic cell culture systems examined cytotoxicity, mitochondrial toxicity, impact on drug transporter proteins, and covalent binding.
View Article and Find Full Text PDFPest Manag Sci
January 2025
Unidad Mixta Gestión Biotecnológica de Plagas UV-IVIA, Department of Genetics, Institut de Biotecnologia i Biomedicina, Universitat de València, Valencia, Spain.
Background: The rising demand for environmentally friendly pest control highlights the importance of understanding the interaction between natural enemies and pesticides. Amblyseius swirskii, a predatory mite extensively used in biocontrol, plays a crucial role in managing pest populations in agricultural systems. Integrating this mite with selective pesticide use within integrated pest management (IPM) would significantly advance pest control and may reduce pesticide residues in the environment and agricultural produce.
View Article and Find Full Text PDFBackground: Polyunsaturated fatty acids are metabolized by cytochrome P450 (CYP450) into anti-inflammatory, pro-resolving epoxides, which are rapidly converted to inactive and cytotoxic diols by soluble epoxide hydrolase (sEH). Increased CYP450-sEH metabolites are associated with worse cognition in type 2 diabetes mellitus (T2DM), and greater white matter hyperintensities (WMH) in patients with stroke. We examined whether the relationship between linoleic acid (LA)-derived CYP450-sEH metabolites (oxylipins) and small vessel disease (SVD) markers differ across diabetes status.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) affects millions of Americans, with potential future increases without breakthroughs in treatment. IGC-AD1, a novel formulation comprising of delta-9 tetrahydrocannabinol ("THC") and melatonin, is being studied in AD-associated agitation. THC is predominantly metabolized by cytochrome P450 and specifically by CYP2C9.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Background: 20-hydroxyeicosatetranoic acid (20-HETE) is a potent vasoconstrictor synthesized by the CYP4F2 enzyme. The CYP4F2 missense variant rs3093105 A>C (W12G) has been implicated in hypertension and stroke, risk factors for Alzheimer's disease (AD), and with decreased 20-HETE activity. To explore the potential role of the CYP4F2/20-HETE pathway and AD, this study investigated associations between the rs3093105 variant and AD phenotypes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!